Johnson
The New Jersey-based company’s candidate vaccine is the only one that requires a single vaccine and, unlike its competitors, the vaccine wants to stay at below-zero temperatures. These two points can facilitate the distribution of the vaccine.
The trial begins one day after the death toll in the United States exceeded 200,000. The race for a vaccine is underway, and federal fitness officials suggest that limited stocks of a COVID-19 vaccine may be available until the end of the vaccine. Year.
Pfizer and Moderna began Testing Phase 3 at the end of July. AstraZeneca has also introduced Phase 3 tests, however, the US aspect is recently suspected because a British player has suffered a serious adverse reaction.
Johnson’s candidate vaccine
The vaccine combines the genetic appearance of the coronavirus with a deactivated adenovirus to cause an immune formula response. Adenovirus is known to cause cold-type symptoms, however, the editing used in the vaccine has been genetically modified for use.
Multinational trials will recruit up to 60,000 participants in 215 in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and the United States.
Vaccine trials are conducted in collaboration with Operation Warp Speed, the federal government’s COVID-19 vaccine acceleration program.
This is expected until at least early 2021. Intermediate effects of Phase 3 trials can take up to 2 months.
Phase 3 soft green entry was based on the promising effects of previous trials. So far, the candidate vaccine has demonstrated an adequate protective profile and ability to create an immune reaction opposed to coronavirus after a single dose. This knowledge is expected to be published, soon on medRxiv.
In phase 3 trials, a dose of the singles vaccine will be compared to a placebo. The FDA has said that a vaccine will have to protect at least 50% of the population to be considered effective, however, corporations are looking outside of the higher percentages.
The one studied for Johnson’s phase 3 trials
Dr Paul Stoffels, Johnson’s Chief Scientific Officer
He and his content are provided “as is”.